Answer
Hypersensitivity reactions, including isolated angioedema events, have been reported in the post-marketing setting in patients treated with Lutathera (lutetium (177Lu) oxodotreotide).
Sources for this answer
- Lutathera 370 MBq/mL solution for infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked